Pharmaceutical major FDC Ltd reported consolidated revenue from operations of ₹6.68 billion and a net profit of ₹1.32 billion for the June quarter. The Mumbai-headquartered maker of Electral and ophthalmic solutions maintained strong operational margins driven by steady domestic formulation demand and disciplined raw material cost management.
MUMBAI — Indian pharmaceutical manufacturer FDC Ltd announced its consolidated financial performance for the June quarter, reporting operational revenue of ₹6.68 billion alongside a net profit of ₹1.32 billion. The company disclosed these first-quarter financial figures in a mandatory regulatory filing submitted to stock exchanges following the board of directors meeting held to review and approve the audited accounts.
The performance highlights steady demand across the firm's core therapeutic portfolios, led by flagship oral rehydration salts (Electral), ophthalmic formulations, anti-infectives, and active pharmaceutical ingredients (APIs). As domestic healthcare consumption accelerates across urban and rural markets, FDC Ltd has maintained strong distribution momentum across domestic retail pharmacy networks and export channels.
Detailed Breakdown of FDC Consolidated Financial Performance
During the April–June quarter, FDC Ltd recorded consolidated revenue from operations reaching ₹6.68 billion (₹668 crore). The financial top-line expansion reflects sustained prescription volumes across primary healthcare categories, particularly during the peak summer months when demand for oral rehydration formulations typically surges.
| Financial Metric | First Quarter Performance |
| Consolidated Revenue from Operations | ₹6.68 Billion (₹668 Crore) |
| Consolidated Net Profit (PAT) | ₹1.32 Billion (₹132 Crore) |
| Core Product Lines | Electral (ORS), Enerzal, Ophthalmic Solutions, APIs |
| Primary Geographic Markets | India, United Kingdom, United States, Emerging Markets |
Consolidated net profit for the quarter reached ₹1.32 billion (₹132 crore), supported by operational productivity, raw material cost management, and disciplined overhead expenses across manufacturing plants. FDC maintained positive gross margins despite ongoing price controls enforced on essential medicines in the domestic market.
Manufacturing Infrastructure and Therapeutic Portfolio Strategy
The announcement of the FDC Ltd June Quarter Financial Results underscores the company's established position in the Indian formulations market. Known for pioneering WHO-formulated oral rehydration salts under the brand name Electral, FDC operates multi-location manufacturing facilities across Maharashtra, Goa, and Himachal Pradesh, compliant with global regulatory authorities including the US FDA and UK MHRA.
In addition to oral rehydration solutions, FDC retains market leadership in ophthalmic care, anti-fungal treatments, and pediatric formulations. The company's specialized active pharmaceutical ingredient (API) synthesis units in Roha and Waluj supply key chemical inputs internally, protecting product margins against international supply chain disruptions.
Indian Pharmaceutical Market Context and Sector Trends
The broader Indian pharmaceutical and formulation sector continues to experience steady volume growth, supported by rising healthcare awareness, expanding health insurance coverage, and steady domestic demand. High-margin specialty formulations and OTC rehydration products offer stable revenue cushions against pricing regulations imposed by the National Pharmaceutical Pricing Authority (NPPA).
Industry analysts note that formulation companies maintaining strong brand equity in OTC and acute therapeutic categories benefit from high brand recall and robust retail distribution channels. With continuous investments in bioequivalence studies and product quality compliance, Indian pharma majors are well-positioned to expand export footprints across regulated and semi-regulated international markets.
Official Sources and Corporate Filings
Official sources confirmed the financial performance following statutory board approvals and stock exchange communications:
According to official filings submitted under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the financial report was reviewed by statutory auditors and approved by the Board of Directors, affirming that operational liquidity remains well-balanced to support ongoing capital expenditure projects.
Company disclosures further confirmed that capital allocation priorities will focus on expanding manufacturing automation, regulatory compliance infrastructure, and localized research programs.
Official Statements and Executive Remarks
Corporate representatives highlighted the operational performance in mandatory market notifications filed with exchange desks.
"According to officials, the first-quarter operational results reflect sustained market leadership in core formulation segments and consistent operational efficiency across domestic and international distribution networks," stated the corporate disclosures.
Why It Matters: Impact on Investors, Healthcare, and Consumers
The quarterly performance of FDC Ltd carries direct practical implications across key pharmaceutical and capital market stakeholders:
For Investors and Shareholders: Consolidated net profit of ₹1.32 billion on ₹6.68 billion revenue reinforces earnings stability and capital management discipline.
For Healthcare Professionals and Patients: Consistent manufacturing output ensures uninterrupted supply of essential WHO-formula rehydration products and sterile ophthalmic medications.
For the Pharmaceutical Industry: Strong financial metrics among mid-tier formulation leaders validate the resilience of domestic acute therapeutic demand.
Key Facts at a Glance
Quarterly Revenue: FDC Ltd reported consolidated revenue from operations of ₹6.68 billion for the June quarter.
Quarterly Profit: Consolidated net profit after tax reached ₹1.32 billion.
Key Brands: Manufacturer of market-leading brands including Electral, Enerzal, and Zocon.
Manufacturing Base: Operates US FDA and UK MHRA approved plants across India.
Frequently Asked Questions
What were the key financial results for FDC Ltd in the June quarter?
FDC Ltd reported consolidated revenue from operations of ₹6.68 billion and a consolidated net profit of ₹1.32 billion for the June quarter.
What are FDC Ltd's main pharmaceutical products?
FDC Ltd is best known for its oral rehydration salts (Electral), energy drinks (Enerzal), ophthalmic formulations, anti-infectives, and specialized active pharmaceutical ingredients (APIs).
Where are FDC Ltd's shares listed?
FDC Ltd's equity shares are publicly traded on the National Stock Exchange of India (NSE) and the BSE Limited.
Source: Official financial disclosures and regulatory filings submitted to the National Stock Exchange of India (NSE) and the BSE Limited, alongside investor information published on FDC Limited Investor Relations.
